



ASX RELEASE

PEER-REVIEWED “THE REDISCOVERY OF BISANTRENE” PUBLISHED

- Published in *International Journal of Cancer Research & Therapy*
- Article expected to underpin renewed interest in Bisantrene

20 July 2017 – Race Oncology Limited (ASX: **RAC**) announced today the publication of an article titled: “The Rediscovery of Bisantrene: A Review of the Literature” in the *International Journal of Cancer Research & Therapy*. The author of the article is Dr John Rothman, Chief Scientific Officer of Race Oncology.

The *International Journal of Cancer Research & Therapy* is an open-access peer-reviewed journal that publishes the latest findings and research in cancer. A link to the article can be found on the Race Oncology website under ‘Investors’.

“This is the first significant published article on Bisantrene in more than two decades,” noted Race CEO, Peter Molloy. “It represents an excellent summary of the history and clinical utility of Bisantrene and should be an important resource for oncologists who use Bisantrene.” The Company indicated that it plans to use the published article to support its Named Patient Program sales in Europe and Korea.

The abstract of the article is provided below:

ABSTRACT

Bisantrene is an anthracene with anthracycline-like antitumor activity that has been the subject of over 60 clinical trials but which was lost for over 30 years due to various merger and acquisition transactions. In over 2000 patients, bisantrene has been well tolerated and shown to lack the cardiac dose-limiting toxicity of the anthracycline class and perhaps to lack a propensity to induce multi-drug resistance. Aside from inhibition of topoisomerase II, macrophage-activating activity and telomerase inhibiting activity have been reported for this agent. Within an extensive body of publications comprising over 40 clinical trials, clinical activity has been documented in a number of indications, including lymphoma, refractory breast cancer, and ovarian cancer. In 7 phase 2 trials, therapeutic utility was seen in acute myeloid leukemia (AML) comparable or superior to drugs currently in development. Although never marketed, bisantrene was approved for the treatment of AML in France in 1991 under the name Zantrene. Originally developed in the 1970s and 1980s, bisantrene is a well-tolerated and useful drug that has resumed clinical development.

About Race Oncology Limited

Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first asset is a chemotherapy drug, Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company’s goal is to complete development of Bisantrene and bring Bisantrene to market.

Information Contacts:

Race Oncology

Peter Molloy, Managing Director & CEO
E: pmmolloy@raceoncology.com
W: www.raceoncology.com